GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (LTS:0NZU) » Definitions » Valuation Rank

Zealand Pharma A/S (LTS:0NZU) Valuation Rank


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Zealand Pharma A/S Valuation Rank Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (LTS:0NZU) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (LTS:0NZU) » Definitions » Valuation Rank
Comparable Companies
OCSE:ALK B OCSE:BAVA OCSE:GUBRA OCSE:PEG A OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB XKRX:068270 BMRN
Traded in Other Exchanges
ZLDPF:USA ZEALc:UK ZEAL:Denmark 22Z:Germany
Address
Sydmarken 11, Soborg, DNK, DK-2860
Website
https://www.zealandpharma.com
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.